<div>
  <p>
  </p>
  <ul>
    <li>
      <p>
        Illumina announced that the company will divest GRAIL via a third-party sale or capital markets transaction, as per the European Commission's divestiture order, to finalize the terms by the second quarter of 2024.
      </p>
    </li>
    <li>
      <p>
        On December 15, the US Fifth Circuit Court of Appeals issued its decision relating to Illumina vs. the Federal Trade Commission. Considering this opinion, Illumina has opted not to pursue further appeals of this decision.&nbsp;
      </p>
    </li>
    <li>
      <p>
        GRAIL would continue to be held separately, along with committed funding from Illumina for the company's business through the divestment process. Prior to this, Illumina had spun off GRAIL in 2016 but retained a 12% stake and subsequently reacquired the company in 2021.
      </p>
    </li>
    <li>
      <p>
        GRAIL has developed the Galleri test, the first clinically validated MCED test that reportedly can detect a signal shared by more than 50 types of cancer with 99.5% specificity and predict the cancer signal origin with high accuracy to help guide the next steps.&nbsp;
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://www.illumina.com/company/news-center/press-releases/press-release-details.html?newsid=fcc14ca0-2c74-4925-aabd-0ed940ee8c29">
      Press release
    </a>
  </p>
  <p>
  </p>
</div>


Precision Medicine

<div>
 <p>Illumina plans to divest GRAIL as part of a European Commission order. This will involve a sale or capital market transaction, expected to be finalised by Q2 2024. Following a US Court decision, Illumina won't pursue further legal appeals. GRAIL will continue operating separately with financial support from Illumina during the divestment process. Illumina reacquired GRAIL in 2021, having originally spun it off in 2016. GRAIL's Galleri test, a highly accurate tool capable of detecting signals from over 50 cancer types, will likely be central to future operations.</p>
</div>

Illumina to divest GRAIL after US Fifth Circuit Court of Appeals decision

PROMINENT_CATEGORY

<div>
 <ul>
  <li>
   <p>Genetic testing company Grail is conducting a study on its Galleri multi-cancer early detection test. The study specifically involves Medicare beneficiaries from racially and ethnically diverse backgrounds in underserved communities. Medicare will cover the test and associated services for participants in the study.</p>
  </li>
  <li>
   <p>The Galleri test is designed to detect cancerous changes earlier than current methods. The study aims to include up to 50,000 Medicare beneficiaries who will receive regular Galleri testing in addition to usual care. The goal is to observe the potential benefits of early multi-cancer detection.</p>
  </li>
 </ul>
</div>

All Updates

Illumina to divest GRAIL after US Fifth Circuit Court of Appeals decision

Grail launches study to evaluate impact of Galleri multi-cancer detection test

GRAIL, Whitman-Walker Institute, and Cancer Support Community partner to study health equity in cancer

Carrum Health partners with Grail to include Galleri test as part of oncology offering to employers

Grail partners with health systems for clinical trial study

Grail collaborates with PINC AI to enhance patient access to Galleri